Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076492 · ClinicalTrials.gov registry record · Phase 2
NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485
A Phase 2 study of Parkinson Disease, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
- 1
- Study location
NCT00076492 is a Phase 2 study of Parkinson Disease that has completed, run by University of Rochester. The registered enrollment target is 195 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00076492, a Phase 2 study of Parkinson Disease, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to assess the impact of CoQ10 and GPI 1485 on the progression of Parkinson's disease, in order to determine whether it is reasonable to proceed with further study of either of these agents.
Conditions Studied
Interventions
- DRUG CoQ10
- DRUG GPI 1485
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076492
The ClinicalTrials.gov registry entry for NCT00076492 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which CoQ10 is the first listed.
NCT00076492 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00076492 about?
NCT00076492 is a clinical study titled "NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485". The goal of this study is to assess the impact of CoQ10 and GPI 1485 on the progression of Parkinson's disease, in order to determine whether it is reasonable to proceed with further study of either of these agents.
What is the current status of trial NCT00076492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2004-01. Estimated completion is 2005-09.
What conditions does trial NCT00076492 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT00076492?
The interventions under investigation include: CoQ10 (DRUG), GPI 1485 (DRUG).
Who is sponsoring clinical trial NCT00076492?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00076492 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.